Clinical Trials Logo

Filter by:
NCT ID: NCT04009720 Terminated - Clinical trials for Aortic Valve Stenosis

RESPOND EDGE Post Market Study

RESPOND EDGE
Start date: October 11, 2019
Phase:
Study type: Observational [Patient Registry]

The purpose of the RESPOND EDGE post market study is to collect real world clinical and device performance outcomes data with the Lotus Edge™ Valve System used in routine clinical practice to demonstrate that the commercially available Lotus Edge Valve System is a safe and effective treatment for patients with severe calcific aortic stenosis.

NCT ID: NCT04008550 Terminated - Clinical trials for Pulmonary Hypertension

Prognostic Impact of the Evolution of PAH 3 Months After TAVI (HTP-TAVI)

HTP-TAVI
Start date: March 6, 2019
Phase: N/A
Study type: Interventional

Aortic stenosis (AS) is the most frequent valvulopathy in Western countries. The prevalence of AS is constantly increasing due to the aging of the population. Several studies have shown that pulmonary arterial hypertension (PAH) was common in AS patients referred for TAVI and that it was an independent predictor of mortality after TAVI. Currently, there is no data in the literature regarding the evolution and prognosis value of PAH measured using right heart catheterization (reference method). PAH could either regress after TAVI or continue to progress despite the treatment of valvulopathy, resulting in a refractory right heart failure that can lead to death. The hypothesis of this study is that patients with PAH before TAVI procedure and at the 3-month follow-up visit (PAH persistence) have an increased risk of cardiovascular mortality compared to patients with no PAH at 3 months or having a significant reduction of their PAH (PAH regression). The aim of the study is to evaluate the prognostic impact of the evolution of PAH after TAVI in 424 patients using right heart catheterization.

NCT ID: NCT04007146 Terminated - Cardiac Output Clinical Trials

Systematic Calculation of HyperOxygenation Transit Time

SCHOTT
Start date: March 1, 2020
Phase: N/A
Study type: Interventional

Cardiac output (CO) is an essential physiological parameter of healthy person or illness. In clinical practices, all methods of measuring the CO(Fick method, thoracic impedance, esophageal echodoppler etc) contain limit. Each method are dangerous or hard to implement. CO is probably determining element of blood transit time and thus the availability of oxygen between the central organs (heart, lung) and the peripheral organs (leg, arms). Our hypothesis is transcutaneous oxymetry mesurement with oxygen inhalation, to cause a transient hyperoxia, can be used to determinate blood transit time between central organs and peripheral organs. This simple method will be non invasive technique.

NCT ID: NCT04007133 Terminated - Clinical trials for Non-insulin-dependent Diabetes

Statin Compliance of Patients With Non-insulin-dependent Diabetes

DIOS
Start date: January 31, 2018
Phase:
Study type: Observational

The diabetic population has an increased cardiovascular risk compared to the general population. Hydroxymethylglutaryl-CoA reductase (HMG-CoA reductase) inhibitors, or "statins", are considered as the standard treatment for hypercholesterolemia. Many patients with non-insulin-dependent diabetes are prescribed with statins, both for primary prevention, before the first cardiovascular event, and as secondary prevention, to avoid recurrence. However, compliance to these drugs may be difficult due to polypharmacy, side effects (myalgia) or tiredness. The purpose of this study is to determine the compliance of diabetic patients with statins searching for important factors which could favor adherence.

NCT ID: NCT04003610 Terminated - Clinical trials for Metastatic Urothelial Carcinoma

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Start date: May 14, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received prior treatment.

NCT ID: NCT04000282 Terminated - Plasma Cell Myeloma Clinical Trials

First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Start date: August 19, 2019
Phase: Phase 1
Study type: Interventional

Primary Objectives: - Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B - Dose Expansion Part B: To assess the antitumor activity of single agent of SAR442085 at the RP2D in patients with RRMM Secondary Objectives: - To characterize the safety profile of SAR442085 - To characterize the pharmacokinetics (PK) profile of SAR442085 when administered as a single agent - To evaluate the potential immunogenicity of SAR442085 - To assess preliminary evidence of antitumor activity in the Dose Escalation Part A

NCT ID: NCT03992716 Terminated - Critical Illness Clinical Trials

Reaching Protein Target With SmofKabiven® Extra Nitrogen vs Olimel N9E During the Early Phase of Acute Critical Illness

Start date: November 26, 2019
Phase: Phase 4
Study type: Interventional

The main focus of the study is to show that SmofKabiven® extra Nitrogen, in a realistic clinical setting, enables to meet high protein requirements in patients during the first week after onset of critical illness, without risk of overfeeding with energy.

NCT ID: NCT03992157 Terminated - Cerebral Infarction Clinical Trials

Evaluation of Ambulatory ECG Telemetry for the Early Detection of Atrial Fibrillation During Hospital Assessment of Cerebral Infarction

TELEMETRIE
Start date: December 27, 2018
Phase: N/A
Study type: Interventional

The aim of the study is to show that an ambulatory ECG telemetry monitoring of some patients hospitalized for cerebral infarction increases the frequency of the diagnosis of atrial fibrillation, cause of their stroke, and reinforces the protection against recurrences.

NCT ID: NCT03990064 Terminated - Clinical trials for Stress Disorder, Post Traumatic

Benefits of Relaxation by Music Therapy on PTSD Symptoms

TRACER
Start date: February 1, 2020
Phase: N/A
Study type: Interventional

PTSD is a debilitating mental disorder that may develop after experiencing or witnessing a life-threatening event. With appropriate care, treatment efficiency is variable and around 20% of the patients do not respond to psychological treatment. Complementary treatments are needed. as PTSD implied autonomic nervous system (ANS) dysfonction, complementary treatment focusing on ANS regulation, as welle as musicotherapy, may have an interest.

NCT ID: NCT03988192 Terminated - Clinical trials for Lung Cancer, Non-small Cell

Volatile Organic Compounds in Exhaled Air and Sweat of Patients Treated by Immunotherapy for Lung Cancer: Research on Biomarkers for Early Therapeutic Response

Immuno-VOC
Start date: August 28, 2018
Phase: N/A
Study type: Interventional

The study of volatile organic compounds (VOC) detected in exhaled air or in sweat, is an innovative research area for respiratory diseases. The volatolomic analysis can be done either by the technique of the mass spectrometry which allows the identification of each VOC in the exhaled air or by the technique of electronic nose, simpler and faster, which provides an idea of the general profile of the VOC without identifying them. The VOC have shown their interest in some situations, such as diagnostic or prognostic tool in patients followed for thoracic tumorous pathology or bronchial or pulmonary vascular diseases. Immunotherapy is a new therapeutic approach used in non small cell lung cancer in a late stage. VOC analysis could allow to identify biomarkers of early response to immunotherapy. The study of VOC could help in the optimisation of immunotherapy prescription in lung cancer.